US Pharma Tariffs in 2026: Rates and Exemptions

Tariffs

Key takeaways

  • As of October 2026, the main US pharma tariffs come from Proclamation 11020, a Section 232 action that sets a default 100% duty on patented pharmaceuticals and associated ingredients listed in its Annex I.

  • The duty started on July 31, 2026 for companies named in Annex III and on September 29, 2026 for all other companies.

  • Products of the EU, Japan, South Korea, and Switzerland and Liechtenstein pay 15% unless a lower rate applies, and the UK rate was reduced to zero.

  • Generic pharmaceuticals and biosimilars are not subject to the Section 232 tariff at this time, and listed specialty categories such as orphan drugs and cell and gene therapies can receive a zero rate.

  • Companies with approved onshoring plans pay 20%, and those that also hold most-favored-nation pricing agreements can pay zero until January 20, 2029.

  • Rates depend on patent status, manufacturer, country and HTSUS line, so confirm each product with your customs broker before you price or ship.

Yes, there are US pharma tariffs in force as of October 2026. The main one is a Section 232 national security tariff on patented pharmaceuticals and their associated ingredients, created by Proclamation 11020 of April 2, 2026. It sets a default 100% duty, lowers it to 15% for products of the European Union, Japan, South Korea, and Switzerland and Liechtenstein, and offers reduced or zero rates for companies that commit to US manufacturing. Generic medicines and biosimilars are outside the tariff for now.

This guide explains how the pharmaceutical tariffs work, who pays what, which imports are exempt, what the effects of tariffs on pharmaceutical industry supply chains look like in practice, and how companies approach tariff mitigation in pharma. Every rate below was checked against the Federal Register and White House texts in October 2026. Tariff rules change through notices and proclamations, so confirm the rate for your exact product and entry date with your customs broker before you commit to a price. For earlier coverage of how the first tariff announcements affected logistics, see our posts on tariff changes and pharma logistics and on how pharma tariffs reshaped life science shipping.

Are there US tariffs on pharmaceuticals?

Yes. As of October 2026, patented pharmaceuticals and associated active pharmaceutical ingredients listed in Annex I of Proclamation 11020 are subject to a Section 232 duty, and many other imports still carry their regular HTSUS duty and, for some countries, a Section 301 duty. The Section 232 tariff is the one that matters most for branded medicines.

The White House proclamation on pharmaceuticals and pharmaceutical ingredients followed a Commerce Department investigation under Section 232 of the Trade Expansion Act of 1962. It was published in the Federal Register on April 9, 2026 as 91 FR 18183. The proclamation cites Food and Drug Administration figures that, as of 2025, about 53% of patented pharmaceutical products distributed in the United States were produced abroad and only 15% of patented APIs by volume were produced domestically. That import reliance is the stated national security basis for the tariff.

The tariff does not replace other duties automatically. The proclamation stacks the regular column 1 duty so that the total equals the Section 232 rate, unless the column 1 rate is higher, and where more than one Section 232 rate could apply, the lowest one is used. For most finished medicines the practical question is therefore which Section 232 rate applies, not how many layers add up.

How the pharmaceutical tariffs fit with other 2026 duties

The landscape changed sharply in early 2026. A CBP rule published on June 24, 2026 explains that the Supreme Court held in Learning Resources, Inc. v. Trump that the International Emergency Economic Powers Act (IEEPA) does not authorize tariffs, and that Executive Order 14389 of February 20, 2026 ended the IEEPA duties. A temporary 10% surcharge under Section 122 of the Trade Act of 1974 followed for 150 days. In July 2026 the US Trade Representative then imposed new Section 301 duties on goods of many economies in a notice published July 28, 2026. That notice exempts certain pharmaceuticals and pharmaceutical ingredients listed in its annexes, and from July 31, 2026 it also exempts patented pharmaceutical articles that already pay the Section 232 duty.

Country guides on our blog cover those layers in detail, including the US-EU trade deal and its 2026 status, US tariffs on Japan and the current tariffs on China and Hong Kong.

What is the 100% tariff on pharmaceuticals?

The 100% tariff on pharmaceuticals is the default Section 232 rate that Proclamation 11020 applies to patented pharmaceuticals and associated ingredients listed in Annex I, including key starting materials. It applies when no lower country rate, onshoring rate or zero-rate category covers the product. People searching for the "100 tariff on pharmaceuticals" or the "Trump pharmaceutical tariff" are usually asking about this rate.

The duty took effect at 12:01 a.m. eastern time on July 31, 2026 for companies listed in Annex III of the proclamation, and on September 29, 2026 for all other companies. The table below shows the main rate tiers as published. It is a summary to help you ask the right questions, not a substitute for the annexes.

Situation

Section 232 rate as of October 2026

Source and condition

Patented pharmaceutical or associated ingredient in Annex I, no other rate applies

100%

Proclamation 11020, clause 3(a)

Company with an onshoring plan approved by Commerce

20%, rising to 100% on April 2, 2030

Clause 3(b), application procedures published May 13, 2026

Product of the EU, Japan, South Korea, or Switzerland and Liechtenstein

15%, unless a lower rate applies

Clause 3(c)

Product of the United Kingdom

0%, for entries on or after July 31, 2026

Notice published August 4, 2026, reducing the rate from 10%

Onshoring company that also has a most-favored-nation pricing agreement with HHS

0% until January 20, 2029

Clause 3(e)

Listed specialty category from an eligible jurisdiction or meeting an urgent US health need

0%

Clause 3(d) and the BIS notice of September 23, 2026

Generic pharmaceuticals, biosimilars and their ingredients

Not subject to the Section 232 tariff at this time

Clause 5

The takeaway is that two shipments of the same therapeutic class can face 100%, 15% or zero, depending on who made them, where they were produced and whether the product is patented. The UK change comes from a Federal Register notice of August 4, 2026, which lowered heading 9903.04.63 for UK products to zero with effect from July 31, 2026.

Can the rates go up?

Yes. The proclamation lets the Secretary of Commerce raise rates for companies, or for jurisdictions in consultation with the Trade Representative, that fail to meet their commitments, with notice in the Federal Register. Onshoring companies must file periodic reports that may be audited, and fraud or misleading statements can lead to prospective and retroactive tariffs. The onshoring rate itself is scheduled to rise to 100% on April 2, 2030. Budget for the rate you pay today, but model what happens if a commitment lapses.

Which pharmaceutical imports are exempt from US tariffs?

As of October 2026, the main exemptions from the Section 232 pharmaceutical tariff are generic pharmaceuticals, biosimilars and their associated ingredients, products of US origin, and specialty categories that qualify for a zero rate. No pharmaceutical import is exempt from all duties by default, so the regular HTSUS rate and any other trade action still need checking.

The September 23, 2026 notice from the Bureau of Industry and Security, published as 91 FR 60360, defines the zero-rate categories and lists the eligible jurisdictions. The categories are:

  • Drugs and associated ingredients where all approved indications are designated as orphan

  • Nuclear medicines

  • Plasma-derived therapies

  • Fertility drugs

  • Cell therapy and gene therapy products

  • Antibody-drug conjugates

  • Medical countermeasures related to chemical, biological, radiological and nuclear threats

  • Animal health products

These products receive the zero rate if they are products of a jurisdiction with a current or forthcoming trade and security framework agreement, or if Commerce approves them as meeting an urgent US health need. The notice lists 19 eligible jurisdictions: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. A product from a country outside that list can still apply through the urgent health need route, one product per application, with its 10-digit HTSUS number, country of origin and importer of record details.

Two practical points often surprise importers. First, the generic exemption is tied to the product being a generic, not to its price or volume, and the proclamation asks Commerce to report within one year on whether action on generics may be needed. Second, a product that pays no Section 232 duty may still need the right Chapter 99 heading on the entry to show why. Ask your broker which heading your chapter 29 and chapter 30 entries now carry and what evidence supports it.

How will tariffs impact the pharmaceutical industry?

Tariffs will impact the pharmaceutical industry mostly through higher landed costs for patented products made abroad by companies without onshoring or pricing agreements, more complex customs entries, and pressure to shift production or sourcing. The size of the effect depends on each company's product mix and agreements, not on a single industry-wide rate.

When people ask how will tariffs impact pharmaceutical industry economics, it helps to separate the effects by who feels them:

  • Manufacturers of patented medicines. The rate a company pays is now partly a function of its own commitments. A firm with an approved onshoring plan and an HHS pricing agreement can pay zero until January 2029, while a competitor shipping the same class of product from a non-agreement country may face 100%.

  • API and starting material suppliers. Annex I covers associated ingredients and key starting materials, so the tariff can reach intermediate shipments, not only finished packs.

  • Generic and biosimilar supply. These products are outside the Section 232 tariff for now, but they can still be affected by Section 301 duties on non-exempt inputs, packaging or equipment, and by the one-year review.

  • Clinical and research supply. Investigational products, comparators and research materials need individual review, because classification and patent status determine whether Annex I applies.

  • Logistics and compliance teams. Entries carry more data, more Chapter 99 headings and more evidence of origin, manufacturer and agreement status, which increases the risk of holds when information is missing.

The broader effects of tariffs on pharmaceutical industry trade are visible in how companies reroute work rather than in a single price change. Expect more production and packaging moves into the United States, more use of eligible jurisdictions, and more attention to drawback, which the proclamation makes available. For a general primer on how duties are assessed on healthcare goods, read our guide to tariffs and duties for healthcare products.

We have not included price forecasts in this guide. Published estimates vary widely and depend on assumptions about agreements that are still being negotiated, so treat any single figure with caution.

How do pharma companies mitigate tariff risks?

Pharma companies mitigate tariff risks by first establishing exactly which rate applies to each product, then using the legal routes the proclamation offers, such as onshoring plans, pricing agreements, eligible-jurisdiction sourcing and drawback, and finally adjusting contracts and logistics to protect margins and supply. Tariff mitigation in pharma starts with data, not with routing.

  1. Map every SKU and ingredient. Record the 10-digit HTSUS number, patent status, manufacturer, country of origin and whether the company appears in Annex III. Our guide to finding the right HS code covers the classification step.

  2. Check each line against the rate tiers. Confirm whether a 15% country rate, a zero-rate category or the generic exemption applies, and keep the evidence on file.

  3. Evaluate onshoring and pricing routes. Commerce published application procedures for company-specific onshoring agreements on May 13, 2026. Legal and regulatory teams should decide whether an application is realistic and what reporting it would require.

  4. Use urgent health need requests where they fit. For a specialty product outside an eligible jurisdiction, the BIS notice describes the information Commerce needs to assess an urgent US health need.

  5. Review drawback. If imported product or ingredients are later exported, drawback may recover part of the duty. Ask your broker to model it before volumes ship.

  6. Revisit contract terms. Decide who carries the duty under your Incoterms and supply agreements, and add clauses for rate changes mid-contract.

  7. Protect cash flow and bond capacity. Higher duties raise the bond amount needed for entries. Review your US customs bond before the first high-duty entry, not after CBP flags an insufficiency.

  8. Clean up entry data. Incomplete manufacturer or origin data is a common reason for holds. Agree on a document pack with suppliers so every shipment arrives with the same evidence.

Logistics choices can support these steps but cannot change a tariff rate. Moving a patented product through a third country does not change its origin, and misdeclaring origin or patent status creates penalty risk. Mitigation is about qualifying for the rate the law allows and planning for the rate you cannot avoid.

What to confirm with your broker before the next entry

Before you book the next shipment of a patented product, confirm four things with your customs broker: the Chapter 99 heading and rate for the entry date, whether your manufacturer is listed in Annex III, what evidence supports any reduced or zero rate, and whether the bond covers the expected duty. If you paid IEEPA duties on entries made in 2025 or early 2026, also ask whether those entries qualify for a refund under CBP's published procedures.

Rates and notices to keep watching

Pharmaceutical tariffs moved several times in 2026 and are likely to move again. The proclamation calls for progress reports on negotiations and allows the President to take other actions if agreements are not reached or not carried out. BIS also said that changes to the list of eligible jurisdictions may be published in future notices. Keep a short watch list: new Federal Register notices citing Proclamation 11020, CBP guidance messages on Section 232 pharmaceutical duties, changes to the Section 301 exemption annexes, and the one-year report on generics.

When a rate changes, the official text is the Federal Register notice or proclamation, and the official tariff line is in the HTSUS search tool from the US International Trade Commission. News summaries are useful for alerts but should not be the basis for a duty calculation.

How Mercury supports pharmaceutical importers

Mercury's customs brokerage team works with healthcare and life science importers on classification, entry data and the documentation that Section 232 and Section 301 claims now require, alongside cold chain and time-critical transport. If your 2027 budget depends on the rate a product will pay, bring the product list, manufacturer details and contract terms to that conversation so the analysis rests on your actual entries.

Share on Linkedin
Share on X
Share on Facebook